Aesica secures major Alzheimer's contract
UK-based Aesica Pharmaceuticals has signed a multimillion-dollar agreement with US biopharmaceutical company Myriad Pharmaceuticals for the supply of R-Flurbiprofen, an active pharmaceutical ingredient for Myriad's investigative drug Flurizan.
UK-based Aesica Pharmaceuticals has signed a multimillion-dollar agreement with US biopharmaceutical company Myriad Pharmaceuticals for the supply of R-Flurbiprofen, an active pharmaceutical ingredient for Myriad's investigative drug Flurizan.
Under the terms of the 10-year agreement, Aesica, the largest supplier of Flurbiprofen-based products in the world, will be the primary supplier of Myriad's worldwide requirements for the compound.
Flurizan is being studied for its ability to lower levels of Amyloid β42, a toxic peptide that is believed to be a chief cause of Alzheimer's disease. A Phase III clinical trial has recently been initiated by Myriad, using Flurizan in approximately 750 patients with mild to moderate Alzheimer's disease at approximately 100 centres in the US.
'This is an important milestone in the development of our company. We have many years of experience with this technology, a patented process and large-scale production capabilities,' said Dr Robert Hardy, managing director of Aesica. 'It is the first of a number of contract manufacturing opportunities that we are working on.'